Objective: Age at menopause and age at the start of the preceding period of cycle irregularity (menopausal transition) show considerable individual variation. In this study we explored several markers for their ability to predict the occurrence of the transition to menopause.
M enopause, defined as the final menstrual period, marks the end of the female reproductive life span. This event occurs at a median age of about 51, but varies from 40 to 60 years. 1, 2 Irrespective of age at menopause, cycle irregularity occurs about 4 to 5 years before the final menstrual period, 3 whereas the end of fertility commences at a median age of 41 years with a distribution similar to that of age at the last menstrual period. 4, 5 We assume that these events follow a time sequence with more or less fixed intervals, with the end of fertility occurring circa 10 years before the age at menopause. 2 The decline of the number of follicles seems to dictate these reproductive events. During the fetal period, the ovaries are endowed with a limited stock of follicles that serve the rest of a woman's reproductive life. At puberty some 300,000 follicles are left, and this number will decline with age, with a more rapid decrease from 37 years on, 6 corresponding with a more pronounced decline in fecundity. 7, 8 When follicle numbers fall below a critical threshold of a few thousand, the menstrual cycle pattern becomes irregular. 9 At menopause, fewer than 1,000 follicles are left. 6 Because of the variation as described in the first paragraph, chronological age is a relatively poor indicator of the stage of reproductive aging in individual women. Recently, a staging system for reproductive aging was proposed (STRAW) with the aim to identify which level of reproductive decline an individual woman has reached. 10 Menopause was used as a key event, preceded by the so-called menopausal transition, when cycles become irregular. Before the start of the menopausal transition, a stage characterized by regular cycles and elevated follicle-stimulating hormone (FSH) levels was discerned, called the late reproductive phase. FSH levels rise on average after the age of 35 years, 11 but younger women also may have higher FSH levels, which are physiological and may be related to receptor polymorphisms and not to ovarian aging. 12, 13 Furthermore, the most substantial changes in FSH levels occur during the menopausal transition, when cycles are already irregular. 14 In addition to FSH, other tests reflecting ovarian reserve are available, which could be of use in assessing an individual's reproductive status. Inhibin B is a product of granulosa cells of the recruited antral follicle cohort and is thought to decline before the FSH rise and, therefore, to be an earlier marker. 15 The number of antral follicles, or antral follicle count (AFC), as assessed by ultrasonography, is likely to represent the size of the primordial follicle pool. 16 Anti-müllerian hormone (AMH), which is produced by primary, secondary, and antral follicles, also has proven to be a promising marker of reproductive decline. 17, 18 In the current study we explored the ability of these endocrine and ultrasound markers to predict the occurrence of the menopausal transition within about 4 years in a group of women with normal fertility in the past.
METHODS

Participants
For an ongoing longitudinal study on ovarian function, healthy female volunteers were recruited in 1996 and 1997. This study is part of that longitudinal study. Women could be included if they were between 25 and 46 years of age and had a regular menstrual cycle of 21 to 35 days, with the next cycle predictable within 7 days. All women had a proven natural fertility, which was defined as having established at least one pregnancy within 1 year after stopping contraceptives, resulting in a normal delivery at term. If a woman used hormonal contraceptives, this had to be stopped at least 3 months before the start of the study. Exclusion criteria were ovarian surgery or ovarian abnormalities. The Institutional Review Board approved the study, and written informed consent was obtained from all participants. The volunteers received monetary compensation for participating.
Of the 162 volunteers initially included, 82 women continued in the longitudinal part of the study. These women were older than were the 80 women who did not continue. Reasons for not participating in the longitudinal part were: wish to continue hormonal contraception (n = 10), pregnancy or lactation (n = 3), disease requiring intervention (n = 3), lack of time (n = 8), or having moved (n = 37). For 19 volunteers, the reason for not participating was unknown.
Study design
Volunteers visited the clinic for the first time (T 1 ) during the early follicular phase of the menstrual cycle (on cycle day 2, 3, or 4), for an assessment of the number of antral follicles by transvaginal ultrasonography (Toshiba Capasee SSA-220A, Toshiba Medical Systems Europe BV, Zoetermeer, The Netherlands) 16 and to provide blood samples. Serum and plasma were separated and stored at −20°C for later estimation of levels of AMH, FSH, inhibin B, and estradiol (E 2 ).
The women returned on average 4 (range 3-5) years later for their second visit (T 2 ). During the T 2 visit, information regarding the menstrual pattern between T 1 and T 2 was obtained. Participants were questioned on mean cycle length and the variability of cycle length.
Outcome measure
No uniform definition for the transition to menopause (cycle irregularity) is available, but recently some definitions based upon increasing variability in cycle patterns have been proposed. 10, 19 We defined the VAN ROOIJ ET AL Menopause, Vol. 11, No. 6, 2004 outcome measure of menopausal transition in two ways: (A) Mean cycle length is between 21 and 35 days, but in the last half year, the next menstrual period is not predictable within 7 days; and (B) Mean cycle length is less than 21 or more than 35 days during the last half year or longer. To be able to determine cycle irregularity, all women should have stopped hormonal contraception at least 3 months before the visit at T 2 . None of the volunteers used hormone therapy (HT) for menopause complaints. Two women were using hormonal contraceptives, and when they stopped, both had a regular cycle pattern in the subsequent half year.
Assays
Levels of FSH and E 2 were measured in plasma with the AxSYM immunoanalyzer (Abbott Laboratories, Abbott Park, IL, USA). The World Health Organization Second International Reference Preparation for human FSH (78/549) was used as a standard in the FSH assay. For FSH, interassay coefficients of variation were found to be 5.7%, 5.7%, and 7.8% at the levels of 5, 26 and 79 IU/L, respectively (n = 80). The E 2 assay has been standardized to gas chromatography/mass spectrometry. Interassay coefficients of variation of the E 2 assay at 185, 330, and 1152 pmol/L were 12.9%, 7.8%, and 5.1% (n = 80), respectively. Serum inhibin B levels were measured using an immuno-enzymometric assay (Serotec, Oxford, United Kingdom) as described by Groome et al. 20 Interassay coefficients of variation were 6.6% and 6.0% at 110 and 770 ng/L, respectively. An ultrasensitive immunoenzymometric assay (Immunotech-Coulter, Marseille, France) was used for the estimation of AMH. 21 The limit of detection (defined as blank + 3SD of blank) was 0.05 µg/L. Intraand interassay coefficients of variation were less than 5% and less than 8%, respectively.
Methods of statistical analysis
Data were analyzed with SPSS 10.1 (SPSS Inc., Chicago, IL) and with GLIM (Generalized Linear Interactive Modeling 4; NAG, Oxford, UK). Because the results of the ovarian reserve tests at T 1 were not normally distributed, values are presented as median with 10 th to 90 th percentiles. For comparisons of ovarian reserve tests performed at T 1 between women with a regular cycle at T 2 and women with an irregular cycle at T 2 , the Mann-Whitney test and Fisher exact test were used. To assess the relationships between ovarian reserve tests and age at T 1 , Spearman correlation coefficients were calculated.
Univariable and multivariable logistic regression analysis were used to assess the relation between ovar-ian reserve markers measured at T 1 and the occurrence of the menopausal transition in the follow-up period of, on average, 4 years. For the multiple analysis, a forward selection with P less than 0.05 for entry was applied. The area under the receiver operating characteristics curve (ROC AUC ) was calculated to assess the ability to discriminate between women whose cycle pattern would become irregular and women whose cycle pattern would remain regular. 22 The ROC AUC may vary between 0.5 (no discriminative power) and 1.0 (perfect discrimination). A bootstrapping sampling procedure was applied in which the selection of the variables was repeated 1,000 times after creating 1,000 new data sets (bootstrapping replicas) by drawing cases with replacement from the original data. The probability that a variable was selected in the stepwise procedure was estimated by this procedure.
RESULTS
Because from one woman no AMH value could be determined due to an insufficient amount of serum, data of 81 women could be analyzed. In 14 volunteers, the cycle became irregular between T 1 and T 2 . Five women did not have a menstrual period during the 6 months preceding the second visit, five had more than two skipped cycles within the last half year, two had skipped at least one cycle in the last half year, and the other two women could not predict the subsequent cycle with a precision of less than 7 days. The median interval between T 1 and T 2 was 3.9 years, ranging from 3.0 to 4.9 years.
Age and ovarian reserve tests assessed at T 1 were compared between women with a regular cycle and with an irregular cycle circa 4 years later (T 2 ) ( Table 1) . Women with an irregular cycle at T 2 were significantly older at T 1 than women still regular at T 2 . They also had The correlation coefficients of the ovarian reserve markers measured at T 1 are presented in Table 2 . AMH and AFC were highly correlated with age and also highly correlated with each other. Lower but significant correlations were present when FSH was correlated with age, AMH, and AFC. Inhibin B was only significantly correlated with E 2 .
In Table 3 , the results of the univariable logistic regression analysis are presented. Age, AMH, AFC, FSH, and inhibin B were significantly associated with the occurrence of the menopausal transition within 4 years. Based on the ROC AUC , AMH, AFC, and age had the best discriminative potential as a single predictor of the menopausal transition. Inhibin B and FSH had a somewhat lower but still discriminative ROC AUC . E 2 levels were not significantly associated with the outcome measure. Neither body mass index [OR (95% CI) 0.93 (0.80-1.09; P = 0.37)] nor smoking [OR (95% CI) 0.27 (0.03-2.21; P = 0.22)] were significantly associated with the occurrence of the menopausal transition.
Because age is known and predictive for cycle irregularity, it is of interest whether extra testing improves prediction. Therefore, we analyzed whether each of the ovarian reserve tests contributed significantly to the prediction of the menopausal transition after correcting for age (Table 3 ). Both AMH and inhibin B were significantly associated with cycle irregularity, taking the effect of age into account. The ROC AUC changed from 0.82 for age as a single predictor to, respectively, 0.89 and 0.88 when AMH or inhibin B was added. If age was known, no significant effect of FSH or AFC was present.
In the multivariable stepwise logistic analysis, the variables AMH, inhibin B, and age were selected in that order. The ROC AUC increased from 0.87 for AMH alone to 0.92 for the total model. The bootstrap procedure indicated that AMH and inhibin B were selected in the majority of cases (respectively, 86% and 72%), whereas age was selected in approximately half of the samples (51%). The other variables AFC, FSH, and E 2 were selected in only a minority of cases (16%, 11%, and 9%, respectively).
DISCUSSION
Menopausal transition (cycle irregularity) is an important reproductive milestone because, at that stage, fertility is most severely compromised. 2 However, during the years before, the reproductive capacity is already impaired. The fact that the median age of (almost) end of fertility is 41 years, whereas the median age of the menopause transition is 46 years, confirms this notion. 2 Therefore, when a woman can be identified to develop an irregular cycle pattern within the three to five years ahead, she is likely to be in her late reproductive phase, 10 with a low chance of becoming pregnant.
Our results suggest that the novel marker AMH is a promising predictor for the occurrence of the menopausal transition in the subsequent 3 to 5 years. Serum AMH concentrations measured at T 1 differed significantly between women who continued to have regular cycles and those who developed an irregular cycle pattern. It was one of the best single predictors and, in more than 80% of the cases, AMH was selected when using the bootstrap procedure.
The other markers, except E 2 levels, also differed between these two groups of women. Inhibin B had a significant additional contribution to the prediction if AMH and age were taken into account, and inhibin B was selected in more than 70% of cases in the bootstrap procedure. AFC was also predictive for cycle irregularity. However, when correcting for AMH or age, AFC was no longer predictive due to the high correlation with both variables ( Table 2) . FSH performed less in Menopause, Vol. 11, No. 6, 2004 predicting cycle irregularity in comparison with AMH, inhibin B, and age because it was selected in only a minority of cases in the bootstrap procedure. E 2 levels were not significantly related to the menopausal transition. The interassay coefficients of variation of the E 2 assay were poorest, which may contribute to this result. However, in daily practice, E 2 assays will always show this variation, and E 2 measurements will, therefore, continue to be not very useful.
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The process of reproductive aging is related to the size of the ovarian follicle pool. 2, 6, 9 A marker giving a good reflection of the follicle pool is potentially suitable for the individual prediction of ovarian senescence. AMH is exclusively produced by granulosa cells of primary, secondary, and antral follicles and, therefore, is a good candidate. 17, 18, 23, 24 In contrast, AFC, inhibin B, and FSH are presumed to reflect directly (AFC, inhibin B) or indirectly (FSH) the size of the antral follicle pool only. AMH was the only ovarian reserve test changing longitudinally in young women, and postmenopausal women all have undetectable AMH levels. 17 Furthermore, serum AMH concentrations are related to the number of oocytes retrieved after controlled ovarian hyperstimulation in IVF treatment, 18, 25 which can be considered as a reflection of ovarian reserve. 26 In the multivariable analysis, the measurement of inhibin B levels added predictive information after controlling for AMH (Table 3 ). It is assumed that low inhibin B levels are indicative for a decline in the number of recruited antral follicles. 15 Therefore, it seems surprising that inhibin B contributed independently to the prediction after AMH was taken into account because AMH also gives a reflection of the antral follicle cohort. The low correlation of inhibin B with AMH ( Table 2 ) and with AFC 27, 28 reflects that inhibin B may not simply represent the number of antral follicles but is more related to changes in the functional state of the follicles with aging.
A marker that already demonstrates a considerable change during the years when the cycle pattern is still regular better identifies the women who are in their late reproductive stage. There are indications that FSH increases only substantially when the cycle pattern has become irregular. 14 Serum AMH concentrations already decline in younger women still having a regular cycle. 17 Chronological age showed a good performance in predicting the menopausal transition; therefore, the additional value of measuring AMH and inhibin B may be questioned. However, women from this study population were of normal fertility in the past and were thought to represent the normal physiological decline of ovarian function. 27 Therefore, age may have performed better in this positively selected study population than it would have in a random population, which does contain women with infertility problems. On the other hand, even in the present study population, a biological variation in reproductive status within age categories will be present and, indeed, AMH and inhibin B independently added prognostic information. It is likely that, in a population also containing infertile women, AMH and inhibin B are even more important predictors.
The results of this study may contribute to the debate about the recently proposed staging system for female 
SERUM AMH AS MARKER FOR MENOPAUSAL TRANSITION
reproductive aging. 10 Currently, FSH is incorporated in this staging system as an endocrine marker to discern the late reproductive phase. Elevated FSH levels and regular menstrual cycles are considered to characterize these years before the transition to menopause. However, FSH performed less well in predicting the menopause transition and was selected only in a minority of cases in the bootstrap procedure, in contrast with AMH and inhibin B. The authors of STRAW already indicated that there might be better markers than FSH to discern the late reproductive phase. FSH was chosen because it can be readily assayed in most laboratories, unlike AMH and inhibin B. 10 Although this was a small study with a limited number of events, it seems that AMH is a better candidate than FSH for predicting the menopausal transition. However, due to the small size, no cutoff values and recommendations can be given at this stage, and larger studies should follow.
CONCLUSION
Serum AMH concentrations alone or in combination with inhibin B are predictive of the occurrence of the menopausal transition in subsequent years. Potentially they seem better markers to reflect the reproductive status of individual women than FSH.
